Impact of Tariffs on Imported Generic Medicines

American President Donald Trump's proposal to impose tariffs up to 200% on imported generic medicines aims to encourage domestic production. However, this initiative faces several challenges and has significant implications for the pharmaceutical industry.

Challenges in Manufacturing Shift

• High costs of production and lengthy regulatory timelines make it difficult to establish a generics manufacturing ecosystem in the US within the proposed two-year transition period.
• Industry experts suggest it would take at least five years to build viable manufacturing capabilities in the US.
• Transferring product registrations and securing necessary approvals extend beyond the duty-free window proposed.

Industry Reactions and Implications

• The proposal affects companies with both US and non-US manufacturing footprints differently: 
  • Aurobindo Pharma and Senores Pharmaceuticals might benefit due to their existing US presence.
  • Dr Reddy’s Laboratories, Lupin, Cipla, and Zydus Lifesciences have some US capacity but remain reliant on imports, which could be negatively impacted.
  • Alkem Laboratories and Torrent Pharmaceuticals may see a neutral impact as their US generics businesses contribute less to cash flows.
• Pharmaceutical stocks declined due to investor concerns about the tariff's potential impact.

Economic and Regulatory Considerations

• Building a US generics manufacturing ecosystem is seen as unrealistic within the proposed timeline due to economic factors.
• Investment in generics is less lucrative, as they account for only 13% of drug spending in the US compared to patented medicines.
• Manufacturing costs in India remain significantly lower, and tariffs might not completely negate this cost advantage.
• Implementation uncertainties remain, especially with the potential change in US administration by 2029.

Response from Indian Pharmaceutical Companies

• Dr Reddy’s Laboratories currently has no plans to shift its manufacturing to the US, awaiting a formal policy decision.
• CEO Erez Israeli stressed that relocating due to tariffs is impractical, with price adjustments being a more likely response if tariffs are enforced.

Overall, while the tariff proposal seeks to promote domestic manufacturing, numerous economic, regulatory, and structural challenges need to be addressed, affecting both US and Indian pharmaceutical stakeholders.